Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P31639

UPID:
SC5A2_HUMAN

ALTERNATIVE NAMES:
Low affinity sodium-glucose cotransporter; Solute carrier family 5 member 2

ALTERNATIVE UPACC:
P31639; A2RRD2

BACKGROUND:
The protein Sodium/glucose cotransporter 2, with alternative names such as Low affinity sodium-glucose cotransporter and Solute carrier family 5 member 2, is crucial for glucose reabsorption in the kidneys. By transporting D-glucose across the plasma membrane, it ensures the conservation of glucose, pivotal for energy production.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Sodium/glucose cotransporter 2 could open doors to potential therapeutic strategies. Its direct link to renal glucosuria highlights its significance in developing treatments aimed at correcting glucose transport defects, thereby mitigating the disease's impact on patients.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.